In this multicenter, single-arm, phase II, prospective clinical trial, we reported the efficacy and safety of the VEGFR2-targeting apatinib combined with PD-1 inhibitor camrelizumab in patients with RM-NPC. The gene discussed is KDR; the disease is nasopharyngeal carcinoma.